VDPHL01 is Veradermics' investigational extended-release oral minoxidil tablet. The company raised $256 million in an oversubscribed IPO and just presented new comparative data at AAD 2026. Here's what the evidence actually shows, and what's still missing.
VDPHL01 is an extended-release oral minoxidil tablet developed by Veradermics (NYSE: MANE), a dermatologist-founded company co-founded by Reid Waldman, MD, and Tim Durso, MD. The company IPO'd in February 2026, with shares more than doubling on debut day. If approved, VDPHL01 would be the first FDA-approved oral non-hormonal treatment for pattern hair loss in both men and women, and the first new FDA-approved prescription hair loss treatment in nearly 30 years.
The formulation uses a proprietary gel matrix for sustained minoxidil release throughout the day. In the male Phase 2 cohort highlighted in this article, the dose was 8.5 mg twice daily (17 mg/day total). The male Phase 3 program also includes an 8.5 mg once-daily arm, and the female Phase 2 uses 4.5 mg once or twice daily.
This is not a new molecule. Minoxidil has been FDA-approved as a topical since the 1980s, and immediate-release oral minoxidil is already widely prescribed off-label for hair loss. What Veradermics has done is reformulate the delivery mechanism. Whether that justifies a new branded product, with the pricing that implies, is the core question.
Immediate-release oral minoxidil reaches peak plasma levels within the first hour (per FDA labeling) and has a plasma half-life of approximately 4.2 hours. That profile was designed to lower blood pressure, not to grow hair. Veradermics' thesis is that this PK profile limits hair growth efficacy while creating unnecessary cardiovascular risk.
The company points to what it describes as a roughly tenfold difference between the plasma concentration associated with hair growth (~1.62 ng/mL) and the level at which cardiac effects emerge (~29 ng/mL). These specific thresholds come from Veradermics' own materials and should be treated as part of their mechanistic hypothesis rather than independently established literature values. VDPHL01 is designed to flatten the curve: lower the peak plasma concentration while extending time above the hair growth threshold.
The more compelling argument is about sulfation. Minoxidil is a prodrug, it requires conversion to minoxidil sulfate via sulfotransferase enzymes (notably SULT1A1) at the hair follicle before it becomes active. This process is capacity-limited and time-dependent. Veradermics' hypothesis is that instant-release (IR) minoxidil's rapid spikes overwhelm this enzymatic capacity, while extended-release delivery maintains steady substrate availability for more efficient bioactivation. If correct, this could address the well-documented interindividual variability that makes some patients "non-responders" to minoxidil.
This is their strongest argument. It is also mostly theoretical, there is no published data showing VDPHL01 actually produces more minoxidil sulfate at the follicle than IR minoxidil. The logic is sound. The proof is not yet in.
In a Phase 2 open-label study, 21 male participants received VDPHL01 at 8.5 mg twice daily for four months. The headline numbers: +47.3 hairs/cm² average increase in non-vellus hair count at 4 months, with +37.5 hairs/cm² as early as 2 months. By 4 months, 90.5% reported "improved" or "much improved" hair coverage.
For context: topical minoxidil 5% typically delivers roughly 13-18 hairs/cm² over 6-12 months. Finasteride delivers roughly 15-20 hairs/cm². If +47.3 holds up in larger trials, it would be a substantial improvement. That is a big "if", this was 21 patients, open-label, no placebo, not peer-reviewed, and only 4 months of data.
At AAD 2026, Veradermics presented a blinded comparative analysis where six alopecia experts reviewed before-and-after photos without knowing which treatment patients received or which photo was baseline. They compared VDPHL01 Phase 2 photos against published JAMA Dermatology data for oral minoxidil 5 mg IR and topical minoxidil 5%. The claims: three times faster onset (2 months vs. 6 months), approximately two times greater response intensity, and 82% of VDPHL01 patients achieving moderate-to-great improvement versus 20% for comparators.
Important caveats: this was a retrospective photo review across different studies, not a head-to-head RCT. The patient populations may differ. The timepoints are unequal (2 months vs. 6 months). And VDPHL01's daily dose (17 mg) is 3.4 times the comparator (5 mg). It is a well-designed marketing study, not Phase 3 evidence.
The real competitor is not topical minoxidil, it is the off-label oral minoxidil that a rapidly growing number of patients already take. Telehealth platforms widely prescribe 1.25-2.5 mg daily at roughly $15-30 per month.
VDPHL01's 17 mg daily dose is 3.4 times the JAMA study comparator of 5 mg/day, and 7-14 times the low-dose telehealth regimens many patients actually use. The extended-release mechanism is designed to make that higher dose safe, but the fundamental question remains: how much of VDPHL01's apparent superiority comes from the ER delivery, and how much from simply taking substantially more minoxidil? No head-to-head trial at equivalent doses exists.
Minoxidil was originally developed as Loniten, an antihypertensive prescribed at 10-40 mg daily with known cardiovascular effects including reflex tachycardia, fluid retention, and an FDA black box warning. VDPHL01's 17 mg daily dose falls within this antihypertensive range. The entire safety case rests on the extended-release mechanism keeping peak concentrations below what Veradermics describes as the cardiac activity threshold.
In Phase 2, no serious adverse events were reported. However, the SEC prospectus lists treatment-emergent adverse events in the male Phase 2 cohort including peripheral edema and asymptomatic orthostatic hypertension. These do not prove serious cardiotoxicity, but they are worth noting, particularly because company top line summaries emphasize the absence of cardiac events without always foregrounding these findings. With only 21 patients over 4 months, the long-term cardiovascular safety question remains wide open. Phase 3 trials (52 weeks, 1,000+ male participants, placebo-controlled) are designed to answer it.
There are several gaps in the evidence that are worth tracking:
No peer-reviewed publications. All data comes from company press releases and conference presentations.
No head-to-head comparison at equivalent dose. We still don't know how much of VDPHL01's results come from the ER mechanism versus simply taking more minoxidil.
Mismatched timepoints. The community has flagged that comparing 4-month VDPHL01 data to 6-month comparator data is not apples-to-apples.
No sulfation proof. The ER bioactivation argument is theoretically sound but has no published data behind it.
Limited formulation detail. The proprietary gel matrix has not been publicly characterized in depth.
On the Phase 3 front, three trials are running concurrently:
Study 302 (NCT06724614): 519 males, two dose arms (8.5 mg QD and BID), 52 weeks. Topline data expected H1 2026.
Study 304 (NCT06972264): confirmatory male trial. Enrollment completed February 2026, topline expected H2 2026.
Female Phase 2/3 (NCT07146022): enrolling 500+ women, with timing to be determined as the study progresses.
Combined male enrollment exceeds 1,000 participants. If Phase 2 signals hold up in this setting, it is a significant milestone. If they do not, the story changes.
Regardless of what happens with VDPHL01, extended-release oral minoxidil is now an emerging category, not a single-product story. Veradermics deserves credit for pushing oral minoxidil optimization through formal clinical development. But the underlying molecule is decades old, off-patent, and well-understood, which means the barrier to developing alternative formulations is low.
On that note, Anagen will be releasing MINX, our own lipid matrix oral minoxidil product, within one month. MINX is developed independently and is not affiliated with Veradermics. We believe ER minoxidil is the right direction for the field, and we intend to make it accessible. More details coming soon.
No. The treatments available today, including minoxidil, finasteride, dutasteride, and microneedling, remain the foundation. Hair loss is progressive. Do not reorganize your protocol around a drug that may not be available until 2028-2029. Start with what works now, and when extended-release options become available, talk to your dermatologist about whether upgrading makes sense.
Is VDPHL01 FDA-approved for hair loss?
No. VDPHL01 is in Phase 3 clinical trials and has not received FDA approval. Potential approval is 2028 at the earliest.
Is VDPHL01 better than regular oral minoxidil?
We do not know yet. Phase 2 data from 21 patients showed substantially higher hair counts than historical comparators, but VDPHL01's daily dose (17 mg) is far higher than what most patients take (1.25-5 mg), and there is no head-to-head trial at equivalent doses. Phase 3 results in 2026 will provide a clearer answer.
How much will VDPHL01 cost?
Veradermics has not disclosed pricing. Given patent protection through 2043, expect branded specialty pricing significantly above generic oral minoxidil ($15-30/month). Alternative extended-release products are in development at more accessible price points.
Veradermics. VDPHL01 pipeline overview. veradermics.com.
Veradermics. Phase 2/3 and Phase 3 enrollment completion. BusinessWire. December 2025, February 2026.
Veradermics. Announces presentations at AAD 2026 Annual Meeting. March 2026.
Veradermics. Upsized IPO pricing. BusinessWire. February 2026.
Veradermics, Inc. SEC Prospectus. February 2026.
Bunick CG, Waldman R, Bader K. Executive Insights: Extended-Release Oral Minoxidil. Dermatology Times. March 29, 2026.
Waldman R. CEO interview: VDPHL01 AAD 2026 data. YouTube. 2026.
Gupta AK, et al. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia. JAMA Dermatology. 2024. JAMA Network
ClinicalTrials.gov. NCT06724614, NCT06972264, NCT07146022.
VDPHL01 is Veradermics' investigational extended-release oral minoxidil tablet. The company raised $256 million in an oversubscribed IPO and just presented new comparative data at AAD 2026. Here's what the evidence actually shows, and what's still missing.
VDPHL01 is an extended-release oral minoxidil tablet developed by Veradermics (NYSE: MANE), a dermatologist-founded company co-founded by Reid Waldman, MD, and Tim Durso, MD. The company IPO'd in February 2026, with shares more than doubling on debut day. If approved, VDPHL01 would be the first FDA-approved oral non-hormonal treatment for pattern hair loss in both men and women, and the first new FDA-approved prescription hair loss treatment in nearly 30 years.
The formulation uses a proprietary gel matrix for sustained minoxidil release throughout the day. In the male Phase 2 cohort highlighted in this article, the dose was 8.5 mg twice daily (17 mg/day total). The male Phase 3 program also includes an 8.5 mg once-daily arm, and the female Phase 2 uses 4.5 mg once or twice daily.
This is not a new molecule. Minoxidil has been FDA-approved as a topical since the 1980s, and immediate-release oral minoxidil is already widely prescribed off-label for hair loss. What Veradermics has done is reformulate the delivery mechanism. Whether that justifies a new branded product, with the pricing that implies, is the core question.
Immediate-release oral minoxidil reaches peak plasma levels within the first hour (per FDA labeling) and has a plasma half-life of approximately 4.2 hours. That profile was designed to lower blood pressure, not to grow hair. Veradermics' thesis is that this PK profile limits hair growth efficacy while creating unnecessary cardiovascular risk.
The company points to what it describes as a roughly tenfold difference between the plasma concentration associated with hair growth (~1.62 ng/mL) and the level at which cardiac effects emerge (~29 ng/mL). These specific thresholds come from Veradermics' own materials and should be treated as part of their mechanistic hypothesis rather than independently established literature values. VDPHL01 is designed to flatten the curve: lower the peak plasma concentration while extending time above the hair growth threshold.
The more compelling argument is about sulfation. Minoxidil is a prodrug, it requires conversion to minoxidil sulfate via sulfotransferase enzymes (notably SULT1A1) at the hair follicle before it becomes active. This process is capacity-limited and time-dependent. Veradermics' hypothesis is that instant-release (IR) minoxidil's rapid spikes overwhelm this enzymatic capacity, while extended-release delivery maintains steady substrate availability for more efficient bioactivation. If correct, this could address the well-documented interindividual variability that makes some patients "non-responders" to minoxidil.
This is their strongest argument. It is also mostly theoretical, there is no published data showing VDPHL01 actually produces more minoxidil sulfate at the follicle than IR minoxidil. The logic is sound. The proof is not yet in.
In a Phase 2 open-label study, 21 male participants received VDPHL01 at 8.5 mg twice daily for four months. The headline numbers: +47.3 hairs/cm² average increase in non-vellus hair count at 4 months, with +37.5 hairs/cm² as early as 2 months. By 4 months, 90.5% reported "improved" or "much improved" hair coverage.
For context: topical minoxidil 5% typically delivers roughly 13-18 hairs/cm² over 6-12 months. Finasteride delivers roughly 15-20 hairs/cm². If +47.3 holds up in larger trials, it would be a substantial improvement. That is a big "if", this was 21 patients, open-label, no placebo, not peer-reviewed, and only 4 months of data.
At AAD 2026, Veradermics presented a blinded comparative analysis where six alopecia experts reviewed before-and-after photos without knowing which treatment patients received or which photo was baseline. They compared VDPHL01 Phase 2 photos against published JAMA Dermatology data for oral minoxidil 5 mg IR and topical minoxidil 5%. The claims: three times faster onset (2 months vs. 6 months), approximately two times greater response intensity, and 82% of VDPHL01 patients achieving moderate-to-great improvement versus 20% for comparators.
Important caveats: this was a retrospective photo review across different studies, not a head-to-head RCT. The patient populations may differ. The timepoints are unequal (2 months vs. 6 months). And VDPHL01's daily dose (17 mg) is 3.4 times the comparator (5 mg). It is a well-designed marketing study, not Phase 3 evidence.
The real competitor is not topical minoxidil, it is the off-label oral minoxidil that a rapidly growing number of patients already take. Telehealth platforms widely prescribe 1.25-2.5 mg daily at roughly $15-30 per month.
VDPHL01's 17 mg daily dose is 3.4 times the JAMA study comparator of 5 mg/day, and 7-14 times the low-dose telehealth regimens many patients actually use. The extended-release mechanism is designed to make that higher dose safe, but the fundamental question remains: how much of VDPHL01's apparent superiority comes from the ER delivery, and how much from simply taking substantially more minoxidil? No head-to-head trial at equivalent doses exists.
Minoxidil was originally developed as Loniten, an antihypertensive prescribed at 10-40 mg daily with known cardiovascular effects including reflex tachycardia, fluid retention, and an FDA black box warning. VDPHL01's 17 mg daily dose falls within this antihypertensive range. The entire safety case rests on the extended-release mechanism keeping peak concentrations below what Veradermics describes as the cardiac activity threshold.
In Phase 2, no serious adverse events were reported. However, the SEC prospectus lists treatment-emergent adverse events in the male Phase 2 cohort including peripheral edema and asymptomatic orthostatic hypertension. These do not prove serious cardiotoxicity, but they are worth noting, particularly because company top line summaries emphasize the absence of cardiac events without always foregrounding these findings. With only 21 patients over 4 months, the long-term cardiovascular safety question remains wide open. Phase 3 trials (52 weeks, 1,000+ male participants, placebo-controlled) are designed to answer it.
There are several gaps in the evidence that are worth tracking:
No peer-reviewed publications. All data comes from company press releases and conference presentations.
No head-to-head comparison at equivalent dose. We still don't know how much of VDPHL01's results come from the ER mechanism versus simply taking more minoxidil.
Mismatched timepoints. The community has flagged that comparing 4-month VDPHL01 data to 6-month comparator data is not apples-to-apples.
No sulfation proof. The ER bioactivation argument is theoretically sound but has no published data behind it.
Limited formulation detail. The proprietary gel matrix has not been publicly characterized in depth.
On the Phase 3 front, three trials are running concurrently:
Study 302 (NCT06724614): 519 males, two dose arms (8.5 mg QD and BID), 52 weeks. Topline data expected H1 2026.
Study 304 (NCT06972264): confirmatory male trial. Enrollment completed February 2026, topline expected H2 2026.
Female Phase 2/3 (NCT07146022): enrolling 500+ women, with timing to be determined as the study progresses.
Combined male enrollment exceeds 1,000 participants. If Phase 2 signals hold up in this setting, it is a significant milestone. If they do not, the story changes.
Regardless of what happens with VDPHL01, extended-release oral minoxidil is now an emerging category, not a single-product story. Veradermics deserves credit for pushing oral minoxidil optimization through formal clinical development. But the underlying molecule is decades old, off-patent, and well-understood, which means the barrier to developing alternative formulations is low.
On that note, Anagen will be releasing MINX, our own lipid matrix oral minoxidil product, within one month. MINX is developed independently and is not affiliated with Veradermics. We believe ER minoxidil is the right direction for the field, and we intend to make it accessible. More details coming soon.
No. The treatments available today, including minoxidil, finasteride, dutasteride, and microneedling, remain the foundation. Hair loss is progressive. Do not reorganize your protocol around a drug that may not be available until 2028-2029. Start with what works now, and when extended-release options become available, talk to your dermatologist about whether upgrading makes sense.
Is VDPHL01 FDA-approved for hair loss?
No. VDPHL01 is in Phase 3 clinical trials and has not received FDA approval. Potential approval is 2028 at the earliest.
Is VDPHL01 better than regular oral minoxidil?
We do not know yet. Phase 2 data from 21 patients showed substantially higher hair counts than historical comparators, but VDPHL01's daily dose (17 mg) is far higher than what most patients take (1.25-5 mg), and there is no head-to-head trial at equivalent doses. Phase 3 results in 2026 will provide a clearer answer.
How much will VDPHL01 cost?
Veradermics has not disclosed pricing. Given patent protection through 2043, expect branded specialty pricing significantly above generic oral minoxidil ($15-30/month). Alternative extended-release products are in development at more accessible price points.
Veradermics. VDPHL01 pipeline overview. veradermics.com.
Veradermics. Phase 2/3 and Phase 3 enrollment completion. BusinessWire. December 2025, February 2026.
Veradermics. Announces presentations at AAD 2026 Annual Meeting. March 2026.
Veradermics. Upsized IPO pricing. BusinessWire. February 2026.
Veradermics, Inc. SEC Prospectus. February 2026.
Bunick CG, Waldman R, Bader K. Executive Insights: Extended-Release Oral Minoxidil. Dermatology Times. March 29, 2026.
Waldman R. CEO interview: VDPHL01 AAD 2026 data. YouTube. 2026.
Gupta AK, et al. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia. JAMA Dermatology. 2024. JAMA Network
ClinicalTrials.gov. NCT06724614, NCT06972264, NCT07146022.
